Please join the National Coalition for Cancer Research for their upcoming “Cancer 101” Congressional Briefing Series event:
The Cancer “Moonshot” Initiative:
New Frontiers in Cancer Exploration
Monday, April 25, 2016
12:00 – 1:30 pm
485 Russell Senate Office Building
RSVP at firstname.lastname@example.org
Lunch will be served at this widely-attended event.
President Obama has issued a challenge to galvanize the cancer research and patient communities in the effort against cancer through the “Moonshot” initiative announced in his 2016 State of the Union Address.
Much success in our understanding and ability to combat cancer has been achieved through a sustained and coordinated collaboration of basic, epidemiologic, clinical, behavioral and translational research. This commitment to science has revolutionized our ability to prevent and detect many cancers, and to develop personalized forms of cancer treatment and predict their response with enhanced precision. Yet, as we all know, the fight is far from over as too many people today still suffer and die from cancer in all its forms.
The cancer “Moonshot” initiative is bringing together scientists, oncologists, patient advocates, and representatives of the biopharmaceutical industry with renewed collaborative focus and the ambitious objective of consolidating ten years of cancer research in five years. Achieving this outcome will require unprecedented cooperation by all stakeholders to prioritize and focus on the highest impact emerging and unforeseen scientific pathways of cancer research. These efforts raise a number of important questions that we will address on April 25th, including:
- How will scientists be able to achieve 10 years of research in 5 years?
- What types of research would be most appropriate for expedited research and what will it take to accelerate this work?
- How will this initiative help bring new anti-cancer pharmaceutical/biotechnology products to market faster?
- What is the best approach to overcome barriers that inhibit scientific collaboration and information sharing?
- How will patients participate in the program?
- What will be the “benchmarks” of determining the impact of the initiative?
- How will this set the trajectory for future cancer research?
Please join the National Coalition for Cancer Research for a Roundtable discussion of these and other topics with our distinguished panel of experts:
- Ms. Wendy K.D. Selig, President, National Coalition for Cancer Research;
- Richard L. Schilsky, M.D., FACP, FASCO (Moderator), Chief Medical Officer, American Society of Clinical Oncology;
- Linnea Olson – Lung Cancer Survivor, Participant in numerous clinical trials, Artist, Boston, Massachusetts;
- Elizabeth Blackburn, Ph.D., Nobel Laureate, President, The Salk Institute, La Jolla, California;
- Michael B. Atkins, M.D., Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Washington, D.C.;
- Otis W. Brawley, M.D., FACP, Chief Medical Officer, American Cancer Society, Atlanta, Georgia; and
- Sandra Horning, M.D., Chief Medical Officer and head of Global Product Development, Genentech, San Francisco, California.